Tridek-One
French tech company | Builders Republic
About
Clinical-stage biotech developing first-in-class CD31 checkpoint agonist bispecific antibodies that selectively suppress pathogenic immune cells — targeting autoimmune and inflammatory diseases where broad immunosuppression causes unacceptable side effects. INSERM spin-off.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2018
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 16 M€ raised since 2020
Funding rounds
- Series A — 2022
Investors
- Bioqube Ventures
- bpifrance
- Pureos Bioventures